RU2020115523A - Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций - Google Patents
Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций Download PDFInfo
- Publication number
- RU2020115523A RU2020115523A RU2020115523A RU2020115523A RU2020115523A RU 2020115523 A RU2020115523 A RU 2020115523A RU 2020115523 A RU2020115523 A RU 2020115523A RU 2020115523 A RU2020115523 A RU 2020115523A RU 2020115523 A RU2020115523 A RU 2020115523A
- Authority
- RU
- Russia
- Prior art keywords
- fibrosis
- agent
- hepe
- subject
- composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 22
- 206010016654 Fibrosis Diseases 0.000 title claims 11
- WLKCSMCLEKGITB-XWJJKCKWSA-N 15-HEPE Chemical compound CC\C=C/CC(O)\C=C\C=C/C\C=C/C\C=C/CCCC(O)=O WLKCSMCLEKGITB-XWJJKCKWSA-N 0.000 title claims 10
- 230000004761 fibrosis Effects 0.000 title claims 10
- 239000000203 mixture Substances 0.000 title claims 7
- 230000002265 prevention Effects 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 claims 12
- 239000003443 antiviral agent Substances 0.000 claims 4
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 3
- 239000002083 C09CA01 - Losartan Substances 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 229960004773 losartan Drugs 0.000 claims 2
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims 1
- 102000011690 Adiponectin Human genes 0.000 claims 1
- 108010076365 Adiponectin Proteins 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 239000005485 Azilsartan Substances 0.000 claims 1
- 102100037853 C-C chemokine receptor type 4 Human genes 0.000 claims 1
- 101710149863 C-C chemokine receptor type 4 Proteins 0.000 claims 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 claims 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 claims 1
- 239000005537 C09CA07 - Telmisartan Substances 0.000 claims 1
- 229940126692 CXCR3 antagonist Drugs 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 239000004971 Cross linker Substances 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 108010072051 Glatiramer Acetate Proteins 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims 1
- 108700011259 MicroRNAs Proteins 0.000 claims 1
- 239000005480 Olmesartan Substances 0.000 claims 1
- 102000009266 Y-Box-Binding Protein 1 Human genes 0.000 claims 1
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 125000005907 alkyl ester group Chemical group 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000002075 anti-alcohol Effects 0.000 claims 1
- 230000003367 anti-collagen effect Effects 0.000 claims 1
- 230000000511 anti-eosinophil effect Effects 0.000 claims 1
- 230000002300 anti-fibrosis Effects 0.000 claims 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 claims 1
- 229960002731 azilsartan Drugs 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 claims 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229940038717 copaxone Drugs 0.000 claims 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 229960004563 eprosartan Drugs 0.000 claims 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 210000001370 mediastinum Anatomy 0.000 claims 1
- 229960005108 mepolizumab Drugs 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 229950007699 mogamulizumab Drugs 0.000 claims 1
- 206010028537 myelofibrosis Diseases 0.000 claims 1
- 210000000651 myofibroblast Anatomy 0.000 claims 1
- 230000001722 neurochemical effect Effects 0.000 claims 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 claims 1
- 229960005117 olmesartan Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000902 placebo Substances 0.000 claims 1
- 229940068196 placebo Drugs 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims 1
- 239000003087 receptor blocking agent Substances 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 230000001850 reproductive effect Effects 0.000 claims 1
- 210000000574 retroperitoneal space Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 229950009513 simtuzumab Drugs 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 229960005187 telmisartan Drugs 0.000 claims 1
- 229960004556 tenofovir Drugs 0.000 claims 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 125000005457 triglyceride group Chemical group 0.000 claims 1
- 229960004699 valsartan Drugs 0.000 claims 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086535P | 2014-12-02 | 2014-12-02 | |
| US62/086,535 | 2014-12-02 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017122758A Division RU2721555C2 (ru) | 2014-12-02 | 2015-12-02 | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2020115523A true RU2020115523A (ru) | 2021-01-27 |
Family
ID=56092410
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020115523A RU2020115523A (ru) | 2014-12-02 | 2015-12-02 | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций |
| RU2017122758A RU2721555C2 (ru) | 2014-12-02 | 2015-12-02 | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017122758A RU2721555C2 (ru) | 2014-12-02 | 2015-12-02 | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10363235B2 (enExample) |
| EP (2) | EP3226873B1 (enExample) |
| JP (2) | JP6986445B2 (enExample) |
| KR (1) | KR20170102879A (enExample) |
| CN (2) | CN112245419A (enExample) |
| AU (2) | AU2015358512B2 (enExample) |
| BR (1) | BR112017011685A2 (enExample) |
| CA (1) | CA2968980A1 (enExample) |
| ES (1) | ES2900593T3 (enExample) |
| IL (2) | IL252431B (enExample) |
| MA (1) | MA41120A (enExample) |
| MX (2) | MX382116B (enExample) |
| PH (1) | PH12017501022B1 (enExample) |
| RU (2) | RU2020115523A (enExample) |
| SG (2) | SG11201704495VA (enExample) |
| WO (1) | WO2016090030A1 (enExample) |
| ZA (2) | ZA201704463B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| EP3068757B1 (en) | 2013-11-15 | 2019-02-27 | DS Biopharma Limited | Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid |
| MX2016008953A (es) * | 2014-01-10 | 2017-02-02 | Dignity Sciences Ltd | Composiciones farmaceuticas que comprenden i5-hidroxi-eicosa- 5,8,11,13,17-pentaenoico ( 15-hepe ) y metodos para tratar el asma y trastornos pulmonares que usan las mismas. |
| JP2018502163A (ja) * | 2015-01-16 | 2018-01-25 | アフィミューン リミテッド | １５−ｈｅｐｅを含む組成物及びそれを使用する方法 |
| JP2018524274A (ja) | 2015-05-13 | 2018-08-30 | ディーエス バイオファーマ リミテッド | １５−オキソ−ｅｐａまたは１５−オキソ−ｄｇｌａを含む組成物、ならびにその作製及び使用方法 |
| CN113230244A (zh) | 2015-12-18 | 2021-08-10 | 艾菲穆恩有限公司 | 包含15-hepe的组合物及其使用方法 |
| US20210315851A1 (en) | 2020-04-03 | 2021-10-14 | Afimmune Limited | Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6180671B1 (en) * | 1998-03-10 | 2001-01-30 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected |
| JP2000191525A (ja) | 1998-12-25 | 2000-07-11 | Nof Corp | 皮膚外用剤組成物 |
| AU2634101A (en) * | 2000-01-06 | 2001-07-16 | Martek Biosciences Corporation | Therapeutic preparations of highly unsaturated fatty acids |
| IL151299A0 (en) | 2000-02-16 | 2003-04-10 | Brigham & Womens Hospital | Aspirin-triggered lipid mediators |
| JP2005179211A (ja) | 2003-12-17 | 2005-07-07 | Idemitsu Kosan Co Ltd | 皮膚外用剤組成物 |
| WO2005063231A2 (en) | 2003-12-31 | 2005-07-14 | Igennus Limited | Formulation containing an eicosapentaenoic acid or an ester thereof and a triterpene or esther thereof |
| US20050239889A1 (en) | 2004-04-26 | 2005-10-27 | Jean Gosselin | In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration |
| EP3285072B1 (en) * | 2006-08-08 | 2020-04-15 | Metabolon, Inc. | Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof |
| US8042070B2 (en) * | 2007-10-23 | 2011-10-18 | International Business Machines Corporation | Methods and system for analysis and management of parametric yield |
| GB0802116D0 (en) * | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| JPWO2009154230A1 (ja) | 2008-06-17 | 2011-12-01 | 持田製薬株式会社 | 非アルコール性脂肪肝炎の予防／改善・治療薬 |
| WO2010120880A1 (en) * | 2009-04-14 | 2010-10-21 | Vertex Pharmaceuticals Incorporated | Treatment of liver diseases with a caspase inhibitor |
| GB0907413D0 (en) | 2009-04-29 | 2009-06-10 | Equateq Ltd | Novel methods |
| WO2012135032A2 (en) * | 2011-03-25 | 2012-10-04 | The Brigham And Women's Hospital, Inc. | Anti-inflammatory particles |
| US20120264824A1 (en) * | 2011-04-15 | 2012-10-18 | Mochida Pharmaceutical Co., Ltd. | Compositions and methods for treating non-alcoholic steatohepatitis |
| JP6185473B2 (ja) * | 2011-09-16 | 2017-08-23 | ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 非アルコール性脂肪性肝炎および非アルコール性脂肪肝疾患を処置するためのガラクト−ラムノガラクツロネート組成物 |
| MX2014004710A (es) | 2011-10-19 | 2014-12-10 | Dignity Sciences Ltd | Composiciones farmaceuticas que comprenden dgla y/o 15-hetre y metodos para usar los mismos. |
| US8293790B2 (en) | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| BR112014013098A2 (pt) | 2011-11-29 | 2017-06-13 | Dignity Sciences Ltd | composições compreendendo ácidos graxos que têm 20 carbonos e métodos de produção e uso dos mesmos |
| US20150057216A1 (en) * | 2011-12-16 | 2015-02-26 | Tarix Pharmaceuticals Ltd. | Angiotensins for treatment of fibrosis |
| US20120264705A1 (en) | 2012-01-26 | 2012-10-18 | Dignity Sciences Limited | Antimicrobial compositions comprising 15-hetre and methods of use thereof |
| US20130267598A1 (en) | 2012-02-23 | 2013-10-10 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same |
| CN110478342A (zh) | 2012-05-10 | 2019-11-22 | 索卢泰克斯Na有限责任公司 | 含有天然专门促消退介质及其前体的具有抗炎活性的油 |
| GB201301626D0 (en) * | 2013-01-30 | 2013-03-13 | Dignity Sciences Ltd | Composition comprising 15-OHEPA and methods of using the same |
| TWI742541B (zh) * | 2013-03-15 | 2021-10-11 | 英商邊緣生物科技有限公司 | 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物 |
| CN113230244A (zh) | 2015-12-18 | 2021-08-10 | 艾菲穆恩有限公司 | 包含15-hepe的组合物及其使用方法 |
-
2015
- 2015-12-01 MA MA041120A patent/MA41120A/fr unknown
- 2015-12-02 CN CN202011279675.6A patent/CN112245419A/zh active Pending
- 2015-12-02 EP EP15865150.5A patent/EP3226873B1/en active Active
- 2015-12-02 ES ES15865150T patent/ES2900593T3/es active Active
- 2015-12-02 CN CN201580074543.0A patent/CN107206008A/zh active Pending
- 2015-12-02 SG SG11201704495VA patent/SG11201704495VA/en unknown
- 2015-12-02 WO PCT/US2015/063488 patent/WO2016090030A1/en not_active Ceased
- 2015-12-02 BR BR112017011685-5A patent/BR112017011685A2/pt not_active Application Discontinuation
- 2015-12-02 AU AU2015358512A patent/AU2015358512B2/en not_active Ceased
- 2015-12-02 SG SG10202010594WA patent/SG10202010594WA/en unknown
- 2015-12-02 KR KR1020177018195A patent/KR20170102879A/ko not_active Withdrawn
- 2015-12-02 RU RU2020115523A patent/RU2020115523A/ru unknown
- 2015-12-02 EP EP21200516.9A patent/EP3988101A1/en not_active Withdrawn
- 2015-12-02 JP JP2017527848A patent/JP6986445B2/ja not_active Expired - Fee Related
- 2015-12-02 RU RU2017122758A patent/RU2721555C2/ru active
- 2015-12-02 MX MX2017007000A patent/MX382116B/es unknown
- 2015-12-02 CA CA2968980A patent/CA2968980A1/en not_active Abandoned
-
2016
- 2016-03-07 US US15/062,636 patent/US10363235B2/en active Active
-
2017
- 2017-05-22 IL IL252431A patent/IL252431B/en unknown
- 2017-05-29 MX MX2021005080A patent/MX2021005080A/es unknown
- 2017-06-01 PH PH12017501022A patent/PH12017501022B1/en unknown
- 2017-06-30 ZA ZA2017/04463A patent/ZA201704463B/en unknown
-
2018
- 2018-06-29 ZA ZA2018/04380A patent/ZA201804380B/en unknown
-
2021
- 2021-05-18 AU AU2021203189A patent/AU2021203189A1/en not_active Abandoned
- 2021-11-10 IL IL287983A patent/IL287983A/en unknown
- 2021-11-29 JP JP2021192836A patent/JP2022031813A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020115523A (ru) | Композиции, содержащие 15-hepe, и способы лечения или предотвращения фиброза с применением указанных композиций | |
| JP2017536380A5 (enExample) | ||
| AU2015320792B2 (en) | Methods of treating liver disease | |
| AU2014320463B2 (en) | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | |
| JP2022186932A (ja) | Ｎｔｃｐ阻害剤によるアテローム性動脈硬化、原発性胆汁性肝硬変およびｎｒｌｐ３インフラマソーム関連疾患の治療 | |
| JP7053478B2 (ja) | Ｆｘｒアゴニストを使用するための方法 | |
| WO2008124384A2 (en) | Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c | |
| JP2011502101A5 (enExample) | ||
| JP2017530163A5 (enExample) | ||
| AU2020203316B2 (en) | Novel regimes of FXR agonists | |
| JP2017522352A5 (enExample) | ||
| KR102218498B1 (ko) | Fxr 작용제들의 조합물 | |
| JP2018524274A5 (enExample) | ||
| EP3817749A1 (en) | Compositions and methods for treating non-alcoholic steatohepatitis | |
| AU2017281980B2 (en) | Wnt inhibitors for use in the treatment of fibrosis | |
| KR102494613B1 (ko) | 단백뇨의 치료 | |
| JP2023507387A (ja) | インテグリン阻害剤を使用する肝疾患の治療の組み合わせ | |
| Steiner et al. | Anti-Fibrotic Therapies from Other Organs: What the Gut Can Learn from the Liver, Skin, Lung and Heart | |
| WO2016085981A1 (en) | Method of inhibiting or treating fibrosis | |
| US9682071B2 (en) | Methods of improving microvascular integrity | |
| Meireles et al. | Simvastatin prevents liver microvascular dysfunction and attenuates liver injury in rats with biliary cirrhosis submitted to hemorrage/resuscitation: 1600 | |
| Burant et al. | Prevention and Reversal of Diabetes |